Dopamine receptor D1, Dopamine receptor D2, Dopamine receptor D3, and Dopamine receptor D4 (DRD1-4)

Dopamine receptors D1, D2, D3, and D4 are a subset of the five known dopamine receptor subtypes (D1-D5) belonging to the G protein-coupled receptor (GPCR) superfamily [1, 2]. They are categorized into two families: the D1-like family (D1) which stimulates adenylyl cyclase, and the D2-like family (D2, D3, D4) which inhibits it [5, 7]. These receptors are primarily expressed in the central nervous system, where they modulate critical functions such as motor coordination, reward-seeking behavior, and executive cognitive processes [1, 6]. Dysregulation of these receptors is central to the pathophysiology of several neuropsychiatric and neurodegenerative disorders, most notably schizophrenia and Parkinson's disease [2, 9]. Pharmacological intervention typically involves either antagonism of D2-like receptors to alleviate psychotic symptoms or agonism to restore motor function in Parkinson's [1, 13]. For instance, atypical antipsychotics like clozapine and olanzapine target multiple receptors in this group to balance efficacy and side effects [11, 13]. However, targeting these receptors often leads to significant side effects, including movement disorders and metabolic disturbances, due to their widespread physiological roles [11, 15]. Research continues to explore selective agonists and antagonists to improve therapeutic outcomes while minimizing off-target effects [3, 5].

Other names

Dopamine D1-D4 receptorsD1-D4 receptorsDRD1DRD2DRD3DRD4

Drugs targeting these receptors act as agonists, antagonists, or partial agonists to modulate dopaminergic signaling. Antipsychotics typically antagonize D2-like receptors (D2, D3, D4) to reduce overactivity in the mesolimbic pathway, while dopamine agonists stimulate these receptors to compensate for dopamine deficiency in Parkinson's disease.